DNCA FINANCE 13D and 13G filings for BioXcel Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2020-03-06 11:13 am Purchase | 2020-03-06 | 13D | BioXcel Therapeutics, Inc. BTAI | DNCA FINANCE | 892,453 4.380% | 891,542 (+97864.11%) | Filing |
| 2020-02-24 09:30 am Purchase | 2020-02-24 | 13D | BioXcel Therapeutics, Inc. BTAI | DNCA FINANCE | 911 5.050% | 31 (+3.52%) | Filing |
| 2020-02-18 10:18 am Purchase | 2020-02-18 | 13D | BioXcel Therapeutics, Inc. BTAI | DNCA FINANCE | 880 4.880% | 80 (+10.00%) | Filing |